Trospium Chloride: Effect in Overactive Bladder

Trospium chloride is the salt form of the quaternary anticholinergic agent trospium commonly used in Germany (brand names Spasmex, Spasmolyt, and generics). The salt form is water-soluble and available in tablets or film-coated tablets for oral administration. Trospium chloride acts peripherally at muscarinic receptors of the bladder smooth muscle and reduces its hyperactivity. Due to its highly polar structure, it barely crosses the blood-brain barrier, which is a significant advantage compared to centrally acting anticholinergics, especially in elderly people.

In clinical practice, trospium chloride is an established therapy for overactive bladder with or without urge incontinence. It shares the mechanism of action with other anticholinergics such as solifenacin, oxybutynin, and darifenacin, but differs through its quaternary structure, which in studies results in less frequent central side effects such as confusion, sleep disturbances, and cognitive decline. The choice of substance depends on individual tolerance, comorbidities, and the desired frequency of administration.

Mechanism of Action

Trospium chloride competitively blocks muscarinic acetylcholine receptors of subtypes M1 to M5, with emphasis on M3 in the smooth detrusor muscle of the urinary bladder. Inhibition of M3 activity reduces involuntary detrusor contractions and thus the urge to urinate. Clinically, this manifests in a reduction of micturition frequency, urge episodes, and incontinence events.

Unlike tertiary anticholinergics such as oxybutynin or atropine, trospium chloride carries a quaternary ammonium group and a permanent positive charge. This property prevents significant passage through the blood-brain barrier, which is why central effects such as sedation, confusion, or dementia deterioration are considerably rarer. For elderly people or patients with cognitive impairment, this pharmacological property is particularly valuable.

Oral bioavailability is low at approximately 10 percent, which is why administration on an empty stomach (at least one hour before a meal) is recommended. The half-life is 5 to 18 hours, depending on the study. Trospium chloride is not metabolized hepatically via CYP enzymes and is predominantly excreted renally in unchanged form. Drug interactions via CYP metabolism are therefore rare, but dose adjustment in renal insufficiency is required.

Areas of Use

• Overactive bladder with imperative urge, frequency, and urge incontinence
• Detrusor hyperreflexia in neurological diseases such as multiple sclerosis or after stroke
• Irritable bladder without demonstrable cause, individualized treatment planning
• Postoperative detrusor hyperactivity after gynecological or urological procedures
• Therapeutic trial in children and adolescents with nocturnal enuresis in specialized settings

Trospium chloride is not first-line for stress incontinence alone, urinary retention, severe gastrointestinal atony, manifest narrow-angle glaucoma, or in patients who are cognitively severely impaired and particularly sensitive to central anticholinergic effects.

Dosage and Administration

Adults: 20 mg twice daily orally, typically in the morning and evening. For better tolerability expectations or as single dosing, 15 mg two to three times daily, depending on the formulation.

Modified Release: 60 mg once daily in the morning, available in some countries.

Administration: on an empty stomach, at least one hour before or two hours after a meal, with plenty of water. Absorption is significantly reduced by food.

Renal Insufficiency: with eGFR below 30 ml per minute, reduce dose to 20 mg once daily or further reduce, because trospium chloride is eliminated renally.

Hepatic Insufficiency: typically no dose adjustment needed, because trospium chloride is not metabolized hepatically.

Elderly Patients: lower CNS penetration is an advantage. With renal insufficiency, adjust dose and monitor clinical tolerability.

Duration of Therapy: effects appear within a few days. Re-evaluation after 4 to 12 weeks is worthwhile to assess therapeutic success. For chronic indications, long-term use is possible.

Side Effects

Very Common: dry mouth, constipation.

Common: nausea, abdominal pain, digestive disturbances, tachycardia, visual disturbances with accommodation disorder, fatigue, headache.

Occasional to Rare: urinary retention, worsening of narrow-angle glaucoma, allergic skin reactions, elevated liver enzymes, gastrointestinal atony, conduction disturbances of the heart.

CNS Note: due to the quaternary structure, central side effects such as confusion, sleep disturbances, and hallucinations are rarer than with tertiary anticholinergics. They can still occur in very sensitive patients or with additional anticholinergic comedication.

Heat Intolerance: anticholinergics reduce sweating, which increases the risk of hyperthermia during heat waves. Pay particular attention to this in elderly people and ensure adequate hydration.

Drug Interactions

• Other Anticholinergics (tricyclic antidepressants, some antipsychotics, classic antihistamines, spasmolytic agents, inhaled anticholinergics): additive anticholinergic effects with confusion, tachycardia, constipation, and urinary retention.
• Cholinesterase Inhibitors (donepezil, rivastigmine, pyridostigmine, galantamine): pharmacological antagonism, mutual weakening of effects.
• Beta Blockers and Antiarrhythmics: with tachycardia under trospium chloride, interaction with cardiac rate possible.
• Gastrointestinal Motility Promoting Agents (metoclopramide, domperidone, prucalopride): mutual weakening of effects.
• Antihypertensives: no direct interactions, but hypotension and fall risk in elderly patients.
• Food: absorption is reduced by food, maintain minimum interval.

Special Precautions

Pregnancy: data limited. Use is not routinely recommended, individual risk-benefit assessment. Breast-feeding: transfer into breast milk not adequately studied, use only after individual counseling.

Children: limited data, use only in specialized urological or pediatric nephrological centers.

Elderly Patients: due to lower CNS penetration compared to oxybutynin, better suited overall, yet caution with cognitive impairment; geriatric lists such as Priscus classify anticholinergics in general as critical.

Before Starting Therapy: history of narrow-angle glaucoma (open or acute), severe gastrointestinal disease with atony, myasthenia gravis, prostatic hyperplasia with residual urine. These constellations are contraindications or situations requiring particular caution.

Lifestyle with Overactive Bladder: adjust fluid intake (evenly throughout the day, reduction in evening), pelvic floor exercises and bladder training, reduction of caffeine and alcohol, weight management in obesity. Trospium chloride complements these measures.

Follow-up Monitoring: with long-term therapy, residual urine measurement and control of renal function. If vision worsens or eye pain occurs, consult an ophthalmologist immediately, as a narrow-angle glaucoma attack can be triggered.

Fitness to Drive: typically retained, with accommodation disorders or fatigue, assess individually.

You May Also Be Interested In

• Trospium, the pharmacological base text on the substance
• Solifenacin, another anticholinergic for overactive bladder
• Oxybutynin, classic anticholinergic with central effect
• Mirabegron, Beta 3 agonist as alternative therapy
• Vibegron, another Beta 3 agonist

Frequently Asked Questions

Sources

• Gelbe Liste, Trospium Chloride Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines on Overactive Bladder and Urinary Incontinence
• German Society of Urology